Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada has approved Pfizer's Eraxis, a new hospital treatment for invasive candidiasis/candidemia in adult non-neutropenic patients. Eraxis will be available to Canadian hospitals early in 2008.
Subscribe to our email newsletter
Pfizer said that Eraxis has been shown to be an effective new agent in the treatment of invasive candidiasis in a Phase III trial involving 47 trial sites in Canada, the US and Europe, of which eight were headed by Canadian researchers.
Bernard Prigent, vice president and medical director, Pfizer Canada, said: “We are very pleased to have the opportunity to develop and bring to patients another important new medicine that is proven to save lives. Pfizer’s role in this R&D demonstrates our commitment to Canadian healthcare by providing the support required to ensure Canadians have access to innovative new medicines.”